Shionogi & Co., Ltd. (OTC PINK: SGIOY, SGIOF, TYO: 4507) was established in 1878, formerly known as Shionogi Shoten Co., Ltd., and changed to current use in 1943 Name, currently headquartered in Osaka, Japan, with 5,222 full-time employees, is a Japanese pharmaceutical company engaged in the research, development, manufacturing and distribution of drugs, diagnostic reagents and medical equipment in Japan and internationally. Shionoyoshi Pharmaceutical Co., Ltd. is listed on the Tokyo Stock Exchange and the Osaka Stock Exchange and is a constituent stock of the Nikkei 225 Stock Index.
Shionogi & Co., Ltd. (SGIOY):
Shionogi & Company, Limited (Shionogi Pharmaceutical Co., Ltd.) is a Japanese pharmaceutical company famous for developing Crestor. Shionogi (“シオノギ”) is also used for medical supplies and brand names. Shionogi’s business origins can be traced back to 1878, and it was incorporated in 1919. It was listed on the first section of the Tokyo Stock Exchange and the Osaka Stock Exchange in 1949. The drugs produced include hyperlipidemia, antibiotics and anti-cancer drugs. On March 30, 2020, Ping An announced that it will take a 2% stake and become the seventh largest shareholder of Shiono Yoshito.
In Japan, it is known as a producer of antibacterial agents and antibiotics. Due to the slow growth of the antibiotic market, Shionogi has partnered with Schering-Plough of the United States ( which merged with Merck in 2009 ) to become the exclusive marketing agent for its products in Japan. Shionogi supported the initial formation of Indian generic drug manufacturer Ranbaxy Pharmaceuticals. In 2012, the company became part of the owner of ViiV Healthcare, a pharmaceutical company specializing in the development of HIV therapies.
Shionoyoshi Pharmaceutical Company mainly focuses on metabolic syndrome, pain, infectious diseases, cholesterol drugs, antihypertensive drugs, depression treatment, prescription drugs, non-prescription drugs and diagnostics. Its main products include Cymbalta ( SNRI antidepressant sold jointly with Eli Lilly ), a serotonin and norepinephrine reuptake inhibitor, used to treat depression, anxiety, diabetic neuralgia, and fibromyalgia Pain, chronic low back pain and osteoarthritis pain; Intuniv, a selective a2 adrenergic receptor agonist, used to treat attention deficit hyperactivity disorder; Xofluza, an endonuclease inhibitor, used Influenza treatment; and Symproic, a mu opioid receptor antagonist, used for cancer pain relief and opioid-induced constipation treatment. Beside this there is:
- Avelox, an antibacterial agent that can treat a variety of infections;
- Claritin, an antihistamine sold in conjunction with Schering-Plough;
- Crestor, a cholesterol drug, was sold to AstraZeneca in 1998 ;
- Differin (developed by Galderma) is a topical retinoid for acne, sold in Japan in combination with Galderma;
- Fortamet (Fortamet)
- Methlyin (methionine)
- Mogadon, a short-term treatment for insomnia;
- Mulpleta, thrombopoietin receptor agonist;
- Osphena, the right to sell estrogen receptor agonists, was sold to Duchesnay in 2017.
In addition, Shiono Yoshihide Pharmaceutical and National University Corporation Kyoto University (National University Corporation Kyoto University) reached a research cooperation agreement, focusing on drug development and medical research for the treatment of mental illness; it has a strategic cooperation with Sage Therapeutics, Inc. for the development of MDD And commercialize SAGE-217 for other indications; cooperate with Hsiri Therapeutics Inc.’s mycobacterial disease treatment license and research; cooperate with Tetra Discovery Partners LLC to develop BPN14770 (a selective phosphodiester) Enzyme 4D allosteric inhibitor) clinical development and commercialization; a collaborative research agreement with PeptiDream Inc. to discover and develop a series of blood-brain barrier penetrating peptide drug conjugates; establish a strategic alliance with Tetra Therapeutics to develop BPN14770 and Its commercialization for the treatment of Alzheimer’s disease, Fragile X syndrome and other indications; and a research agreement with AIM ImmunoTech Inc.